Hawryluk P. Kent
Known title: President & CEOCIK: 0001673991
Hawryluk P. Kent's purchase track record
How the stock did after each of Hawryluk P. Kent's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since February 4, 2025
Stock higher 6 months later
100%
3 months: 67%
Median 6-month return
+110.8%
3 months: +26.8%
Beat the S&P 500
100%
median +95.3% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/13/2026 | MBX | $526K | +26.8% | +110.8% | +15.4% |
| 10/20/2025 | MBX | $273K | +203.2% | +137.4% | +5.5% |
| 2/4/2025 | MBX | $535K | -1.0% | +9.3% | +4.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| MBX | ▼ Sell | Open Market | 607 | $18K | 5/6/2026 | View on chart |
| MBX | ▲ Buy | Open Market | 18,500 | $526K | 3/13/2026 | View on chart |
| MBX | ▲ Buy | Option Exercise | 28,768 | $460K | 2/26/2026 | View on chart |
| MBX | ▲ Buy | Grant | 35,250 | $0 | 2/2/2026 | View on chart |
| MBX | ▲ Buy | Option Exercise | 182,859 | $594K | 10/24/2025 | View on chart |
| MBX | ▲ Buy | Open Market | 20,000 | $273K | 10/20/2025 | View on chart |
| MBX | ▲ Buy | Open Market | 50,000 | $535K | 2/4/2025 | View on chart |
| MBX | ▼ Sell | Other | 283,846 | — | 9/16/2024 | View on chart |
| MBX | ▼ Sell | Other | 115,914 | — | 9/16/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MBX Biosciences to Attend Investor Conferences, Analyst Target Raised
MBX Biosciences will join several investor conferences in November, offering a chance for investors to hear about its pipeline. Stifel has kept a positive stance and lifted its target price to $84. Analysts are debating whether the recent 257% jump has pushed the stock above fair value, while others question if the pullback from a strong year run still leaves room for upside.
MBX Biosciences to Attend Investor Conferences, Analyst Target Raised. MBX Biosciences will join several investor conferences in November, offering a chance for investors to hear about its pipeline. Stifel has kept a positive stance and lifted its target price to $84. Analysts are debating whether the recent 257% jump has pushed the stock above fair value, while others question if the pullback from a strong year run still leaves room for upside.